Ranirestat

Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas[1][2].

Product Specifications

CAS Number

[147254-64-6]

Product Name Alternative

AS-3201

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Aldose Reductase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Ranirestat.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(N1CC2=CC=C(Br)C=C2F)C3=CC=CN3[C@]4(C(NC(C4)=O)=O)C1=O

Molecular Formula

C17H11BrFN3O4

Molecular Weight

420.19

Precautions

H315, H319, H335

References & Citations

[1]Matsumoto T, et al. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux. J Pharmacol Sci. 2009 Feb;109 (2) :203-10.|[2]Toyoda F, et al. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats. J Diabetes Res. 2014;2014:672590.